Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 7:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Normosol-R Clear all
Completed Phase 3 Interventional

Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

NCT03451916
View directory record Official record
Conditions
Hip Fracture
Interventions
PLX-PAD, Placebo
Drug
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
0 Years to 90 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Sacramento, California • Denver, Colorado • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

NCT02501811
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
Mesenchymal Stem Cells (MSC), c-kit+ cells, Placebo (Plasmalyte A)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 3 Interventional

MSCs in COVID-19 ARDS

NCT04371393
View directory record Official record
Conditions
Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions
Remestemcel-L, Placebo
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 8, 2026, 7:50 PM EDT
Withdrawn Early Phase 1 Interventional

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

NCT03591614
View directory record Official record
Conditions
Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
Interventions
DKK1
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 8, 2026, 7:50 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Vigil for Participants With Ovarian Cancer

NCT02346747
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms
Interventions
Vigil, Placebo
Biological · Other
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
26
States / cities
Mobile, Alabama • Irvine, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional Results available

Isotonic Solution Administration Logistical Testing

NCT02345486
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
0.9% sodium chloride, Physiologically balanced fluid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 8, 2026, 7:50 PM EDT
Active, not recruiting Phase 1 Interventional

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

NCT04061746
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mesenchymal Stem Cells (MSCs), Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
Biological · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

hCT-MSCs for COVID19 ARDS

NCT04399889
View directory record Official record
Conditions
COVID, Corona Virus Infection, COVID19
Interventions
Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 8, 2026, 7:50 PM EDT
Completed No phase listed Observational

Effects of IV Chloride Content on Outcomes

NCT02083198
View directory record Official record
Conditions
SIRS, Balanced Fluids, Plasmalyte
Interventions
Not listed
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Deerfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 8, 2026, 7:50 PM EDT
Recruiting Phase 4 Interventional

Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

NCT04040452
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
Continuous ketorolac
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
3 Months to 59 Months
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

NCT05253209
View directory record Official record
Conditions
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions
L-citrulline, Plasmalyte A
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

NCT02930044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Early administration of subcutaneous insulin glargine dose, IV insulin infusion, IV fluid repletion
Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

NCT02097641
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 8, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

Resuscitation With Plasma in Surgical and Trauma Patients With Septic Shock

NCT03366220
View directory record Official record
Conditions
Septic Shock
Interventions
Plasma, Balanced crystalloids
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 8, 2026, 7:50 PM EDT
Recruiting Phase 2 Interventional

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

NCT04476901
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
allogeneic human mesenchymal stem cells (hMSCs), Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 1 Interventional

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

NCT02600130
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Longeveron Mesenchymal Stem Cells, Placebo
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 2 Interventional

Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

NCT00294112
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Charlotte, North Carolina • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 3 Interventional

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

NCT04102371
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional

Balanced Solutions and Plasma Electrolytes

NCT03537898
View directory record Official record
Conditions
Critical Illness, Acidosis, Metabolic
Interventions
Lactated Ringer's, Normosol
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional Results available

Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit

NCT02444988
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury
Interventions
0.9% Saline, Physiologically-balanced isotonic crystalloid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
5,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men

NCT00696618
View directory record Official record
Conditions
HIV Infections
Interventions
Fleet Enema, tap water enema, Normosol-R enema
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 1 Interventional

Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus

NCT03171194
View directory record Official record
Conditions
System; Lupus Erythematosus
Interventions
Low Dose Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 1 Interventional

hCT-MSC Infusion in Adults With Autism Spectrum Disorder

NCT04484077
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism
Interventions
hCT-MSC
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years to 34 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 8, 2026, 7:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT06805487
View directory record Official record
Conditions
Zika Virus
Interventions
TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 8, 2026, 7:50 PM EDT